News & Publications Press Releases Featured Press Releases Nov 4, 2024 EpiBiologics to Present Data Demonstrating Disease-Selective Extracellular Protein Degradation and Platform Breadth at Upcoming Scientific Meetings Press Releases Nov 4, 2024 Press Releases Nov 4, 2024 Press Releases Apr 8, 2024 EpiBiologics Extracellular Protein Degraders Demonstrate Robust Preclinical Anti-tumor Activity and Survival Benefit Press Releases Apr 8, 2024 Press Releases Apr 8, 2024 Press Releases Jul 20, 2023 EpiBiologics Appoints Ann Lee-Karlon as Chief Executive Officer and President, Extends Series A Financing to Over $70 Million Press Releases Jul 20, 2023 Press Releases Jul 20, 2023 Press Releases Mar 22, 2023 EpiBiologics Launches with $50 million Series A Financing to Advance Next-Generation Protein Degradation Platform Press Releases Mar 22, 2023 Press Releases Mar 22, 2023 Publications & Presentations Featured Publications Sep 22, 2022 Modular cytokine receptor-targeting chimeras for targeted degradation of cell surface and extracellular proteins Publications Sep 22, 2022 Publications Sep 22, 2022 Publications Apr 28, 2022 Roadmap for Optimizing and Broadening Antibody-Based PROTACs for Degradation of Cell Surface Proteins Publications Apr 28, 2022 Publications Apr 28, 2022 Publications Jan 4, 2021 Development of Antibody-Based PROTACs for the Degradation of the Cell-Surface Immune Checkpoint Protein PD-L1 Publications Jan 4, 2021 Publications Jan 4, 2021 In the News Featured In the News Apr 8, 2024 AACR 2024: EpiBiologics Advances Degraders of Membrane-Bound Proteins In the News Apr 8, 2024 In the News Apr 8, 2024 In the News Mar 22, 2023 At EpiBiologics, a pair of Genentech alumni wants to make next-gen protein degraders In the News Mar 22, 2023 In the News Mar 22, 2023
